- AbbVie (ABBV) heads into Q2 earnings with analysts forecasting revenue up 8.8% year‑over‑year, accelerating from last year’s 6.6% rise — a key metric for traders monitoring top‑line momentum.
- U.S. lawmakers asked AbbVie for details on data protection and oversight of its China clinical trials, including data security and monitoring at Xinjiang and military-linked hospitals.
TradingView
Key facts: AbbVie (ABBV) Q2 revenue +8.8%; US seeks China trial data
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- NYSE:ABBV
- Language
- English (India)
AbbVie (ABBV) heads into Q2 earnings with analysts forecasting revenue up 8.8% year‑over‑year, accelerating from last year’s 6.6% rise — a key metric for traders monitoring top‑lin